SNYR: Synergy CHC Kompaniya qiymatining sof foydaga nisbati
Synergy CHC Corp (SNYR) kompaniyasining bozor qiymati -0.10 miqdoridagi joriy P/E koeffitsiyentini ko'rsatmoqda, bu esa xomashyo va tashish xarajatlarining ortishi tufayli foyda o'sishining sekinlashishi bilan bog'liq. Synergy CHC Corp o'zining bozor mavqeini mustahkamlash uchun raqamli savdoni va salomatlik mahsulotlarining onlayn targ'ibotini kengaytirmoqda. Biznes himoyasi kosmetika ishlab chiqarishning qat'iy standartlari va taniqli savdo belgilari orqali chakana savdo nuqtalariga eksklyuziv kirish imkoniyati bilan ta'minlanadi.
%20Narxning%20foydaga%20nisbati&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_SNYR_-_Synergy-CHC-Corp_-_Price-to-Earnings-Ratio "Synergy CHC Corp (SNYR): Kapitalizatsiyaning foydaga nisbati 02.04.2025dan 03.10.2026gacha | 👁️GURU.Markets👁️")
Synergy CHC Corp. (SNYR) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Synergy CHC Corp|SNYR - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Synergy CHC Corporation|SNYR - Kompaniya qarzlari|Qarzning sof aktivlarga nisbati Synergy CHC Corp.|SNYR - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz hajmi Synergy CHC|Shoshilinch likvidlik synergychc.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
SNYR - Kompaniyaning sof foydasi|Sof foyda prognozi Synergy CHC Corp|SNYR - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Synergy CHC Corporation|SNYR - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Synergy CHC Corp.|SNYR - EBITDA operatsion foydasi|Sirpanuvchi yil uchun bir aksiya uchun sof foyda Synergy CHC|SNYR - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi synergychc.com|SNYR - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Synergy CHC Corp
Kompaniyaning har tomonlama tahlili:synergychc.com - SNYR
P/E koeffitsiyenti biznesning bozor qiymatini sof foyda orqali qoplash muddatini belgilaydi va obyektiv daromadlar hamda investorlar kutimlari o'rtasidagi muvozanatni aks ettiradi. Synergy CHC Corp. (SNYR) kompaniyasining 12 oylik orqa sirli (TTM) P/E koeffitsiyenti tahlili bozorning nisha salomatlik brendlarining kengayish samaradorligi va raqamli iste'molchi xulq-atvori tahlillarining aniqligi uchun qanchalik yuqori premium to'lov qilishga tayyorligini baholash imkonini beradi.
Raqobatdosh kompaniyalar tahlili
P/E multiplikatori haleon.com|Narx-foyda koeffitsiyenti KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Corp MENS|Ligand Corp (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|perrigo.com - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Liquidia Corp - Kompaniya qiymatining sof foydaga nisbati|GLPG (Galapagos Genomics) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati ANI Pharmaceuticals Corp ANIP|Narxning foydaga nisbati MannKind Corporation (MNKD)|AMPH (amphastar.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|Biznesning o‘zini qoplash muddati ARS Pharmaceuticals Inc (SPRY)|TBPH: Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Aquestive Corp|scpharmaceuticals.com (SCPH) - Narxning foydaga nisbati|Narx-foyda multiplikatori TECX|TNXP (Tonix Pharmaceuticals Holding Corp.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati SXT China SXTC|Narxning foydaga nisbati Eupraxia Pharmaceuticals (EPRX)|BHST (BioHarvest Sciences Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori EXOZ (eXoZymes Inc)|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Oramed|ENTX: Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati MindWalk Holdings, Inc.|ABVC (ABVC BioPharma Inc) - Narx-foyda koeffitsiyenti|Cumberland Corp - Kompaniya qiymatining sof foydaga nisbati|QNTM (Quantum BioPharma Ltd) - P/E multiplikatori|Narx-foyda koeffitsiyenti fibrogen.com (FGEN)|P/E multiplikatori TELO|RANI (ranitherapeutics.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori RLYB (Rallybio)|LEXX - Narx-foyda koeffitsiyenti|PULM: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PTHL (Pheton Holdings Ltd)|APM: P/E multiplikatori|Narx-foyda koeffitsiyenti Lyra Therapeutics Inc.|Narxning foydaga nisbati Impact BioMedical|Kapitalizatsiyaning foydaga nisbati TNF Pharma TNFA|Narxning foydaga nisbati cbdMD, Inc. (YCBD)|PRFX (painreform.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Altamira Therapeutics Ltd. CYTO|LIPO (Lipella Pharmaceuticals Inc) - Kapitalizatsiyaning sof foydaga nisbati|OPTN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pieris Pharma PIRS|Procaps Group S.A. (PROC) - Narxning foydaga nisbati|Narx-foyda multiplikatori PTPI|Narx-foyda koeffitsiyenti QLI|Kapitalizatsiyaning foydaga nisbati Acelyrin Inc. SLRN|Narxning foydaga nisbati TFF Pharma (TFFP)
